Showing 1531-1540 of 5062 results for "".
- Are Sunscreens Overstating Their SPF?https://practicaldermatology.com/news/are-sunscreens-overstating-their-spf/2460629/One out of 12 sunscreens worldwide are likely overstating their sun protection factor, according to research from What’s In My Jar, a London-based AI-powered skincare startup. Using machine learning, What’s In My Jar analyzed formulas of 1,205 sunscreen products in thei
- Avita Therapeutics, Houston Methodist Research Institute to Develop New Ways to Rejuvenate Aging Skinhttps://practicaldermatology.com/news/avita-therapeutics-houston-methodist-research-institute-to-develop-new-ways-to-rejuvenate-aging-skin/2460608/Avita Therapeutics’ is partnering with Houston Methodist Research Institute (HMRI) to identify novel approaches to reverse skin aging and rejuvenate skin with the potential for broader applicability such as scar revision and wound healing. The project seeks to establish
- Bristol Myers Squibb's Deucravacitinib Performs Well in Phase 2 Study in Patients with Psoriatic Arthritishttps://practicaldermatology.com/news/bristol-myers-squibbs-deucravacitinib-performs-well-in-phase-2-study-in-patients-with-psoriatic-arthritis/2460605/Results from an ongoing Phase 2 study evaluating the safety and efficacy of Bristol Myers Squibb's deucravacitinib (BMS-986165) 6mg or 12mg once daily, compared with placebo in
- New Bimekizumab Phase 3 Data Presented at EADVhttps://practicaldermatology.com/news/new-bimekizumab-phase-3-data-presented-at-eadv/2460594/UCB shared detailed results of the head-to-head Phase 3 BE SURE study, which demonstrated that patients treated with investigational IL-17A and IL-17F inhibitor bimekizumab achieved superior skin clearance, as compared to adalimumab, in adults with moderate to severe plaque psoriasis. These findi
- Sklice Goes Over-the-Counterhttps://practicaldermatology.com/news/sklice-goes-over-the-counter/2460581/Sklice (ivermectin) lotion, 0.5% is now approved for OTC sale. Sklice (Arbor Pharmaceuticals) was originally FDA approved as a prescription treatment for head lice infestation in patients six months of age and older in February 2012. “The Rx-t
- Label Update for Enstilar Foam Highlights Long-Term Use in Adultshttps://practicaldermatology.com/news/label-update-for-enstilar-foam-highlights-long-term-use-in-adults/2460575/The US Prescribing Information (USPI) for Enstilar® (calcipotriene and betamethasone dipropionate) Foam from LEO Pharma A/S now includes data on long-term use in adults with plaque psoriasis. The update results from the FDA approving a supplemental New Drug Application (sNDA).
- New from BTL: Emsculpt NEO Launcheshttps://practicaldermatology.com/news/new-from-btl-emsculpt-neo-launches/2460571/The first procedure to combine radio frequency heating and high-intensity focused electromagnetic waves into a single therapy, Emsculpt NEO from BTL, has launched. It is FDA-cleared to eliminate fat cells non-invasively. Emsc
- Alastin SkinCare Hits Canadahttps://practicaldermatology.com/news/alastin-skincare-hits-canada/2460568/Alastin Skincare, Inc. is now available in Caanada via partnership with AVARI Medical Ltd. "Alastin Skincare has established a leadership position in the US, achieving the fastest growth rate in the professional skincare channel for three years in a row. In addition to contin
- Call for Entries: Hacking Dermatology 2020 Innovation Challenge to Focus on Dermatologic Challenges in Skin of Colorhttps://practicaldermatology.com/news/call-for-entries-hacking-dermatology-2020-innovation-challenge-to-focus-on-dermatologic-challenges-in-skin-of-color/2460562/Applications are now being accepted for
- Third RAD Conference Goes Virtual in Decemberhttps://practicaldermatology.com/news/third-rad-conference-goes-virtual-in-december/2460555/With a virtual format, the Third Revolutionizing Atopic Dermatitis (RAD) Conference is slated for December 13-14, 2020. Described by organizers as the first and only global, multidisciplinary conference dedicated to the discussion of evaluation and treatment options for atopi